63 Result(s)
within
Kong** Wu
Cancer Research
-
Chapter
Inhibition of Breast Tumor Stem Cells Expansion by the Endogenous Cell Fate Determination Factor Dachshund
The Dachshund homolog 1 (Dach1) gene encodes a conserved co-repressor protein that, through its interaction with other nuclear proteins in the context of the local chromatin, participates in the regulation of gen...
-
Article
Open AccessDACH1 inhibits cyclin D1 expression, cellular proliferation and tumor growth of renal cancer cells
Renal cell carcinoma (RCC) is a complex with diverse biological characteristics and distinct molecular signature. New target therapies to molecules that drive RCC initiation and progression have achieved promi...
-
Article
Open AccessNotch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application
Through epithelial-mesenchymal transition (EMT), cancer cells acquire enhanced ability of migration and invasion, stem cell like characteristics and therapeutic resistance. Notch signaling regulates cell-cell ...
-
Article
Open AccessNon-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer
Tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR-TKIs) are standard treatments for advanced non-small-cell lung cancer (NSCLC) patients harboring activating epidermal growth factor receptor...
-
Article
Open AccessEmerging roles of Nrf2 signal in non-small cell lung cancer
Non-small cell lung cancer (NSCLC) causes considerable mortality in the world. Owing to molecular biological progress, treatments in adenocarcinoma have evolved revolutionarily while those in squamous lung can...
-
Article
GRIM-19 inhibition induced autophagy through activation of ERK and HIF-1α not STAT3 in Hela cells
Gene associated with retinoid-interferon-induced mortality (GRIM-19), an important subunit of mitochondrial complex I, has been identified as a tumor suppressor, and its reduced expression has been reported to...
-
Article
Open AccessModification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer
The objective of this study was to evaluate the effect of platinum-based drugs on nuclear-factor erythroid2 like 2 (NRF2) signaling in non-small cell lung cancer cell lines with or without Kelch-like ECH-assoc...
-
Article
Open AccessThe expression profile and clinic significance of the SIX family in non-small cell lung cancer
The SIX family homeobox genes have been demonstrated to be involved in the tumor initiation and progression, but their clinicopathological features and prognostic values in non-small cell lung cancer (NSCLC) h...
-
Article
Open AccessProstate-specific IL-6 transgene autonomously induce prostate neoplasm through amplifying inflammation in the prostate and peri-prostatic adipose tissue
The causative role of the pro-inflammatory cytokine IL-6 in prostate cancer progression has been well established at molecular level. However, whether and how IL-6 may play a role in prostate cancer risk and d...
-
Article
Open AccessChimeric antigen receptor T cells: a novel therapy for solid tumors
The chimeric antigen receptor T (CAR-T) cell therapy is a newly developed adoptive antitumor treatment. Theoretically, CAR-T cells can specifically localize and eliminate tumor cells by interacting with the tu...
-
Article
Open AccessRecent advances of highly selective CDK4/6 inhibitors in breast cancer
Uncontrolled cell division is the hallmark of cancers. Full understanding of cell cycle regulation would contribute to promising cancer therapies. In particular, cyclin-dependent kinases 4/6 (CDK4/6), which ar...
-
Article
Open AccessRecent advances of bispecific antibodies in solid tumors
Cancer immunotherapy is the most exciting advancement in cancer therapy. Similar to immune checkpoint blockade and chimeric antigen receptor T cell (CAR-T), bispecific antibody (BsAb) is attracting more and mo...
-
Article
Open AccessDevelopment and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HE...
-
Article
Open AccessEGFR-TKIs resistance via EGFR-independent signaling pathways
Tyrosine kinase inhibitors (TKIs)-treatments bring significant benefit for patients harboring epidermal growth factor receptor (EGFR) mutations, especially for those with lung cancer. Unfortunately, the majori...
-
Article
Open AccessGut microbiome modulates efficacy of immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) therapy is a novel strategy for cancer treatments in recent years. However, it was observed that most patients treated with ICIs could not get benefit from the therapy, whic...
-
Article
Open AccessDACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis
C-X-C motif ligand 8 (CXCL8), known as a proinflammatory chemokine, exerts multiple effects on the proliferation, invasion, and migration of tumor cells via the autocrine or paracrine manner. Conversely, the h...
-
Article
Open AccessBiomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) is a negative modulatory signaling pathway for activation of T cell. It is acknowledged that PD-1/PD-L1 axis plays a crucial role in ...
-
Article
Open AccessOrganoid technology and applications in cancer research
During the past decade, the three-dimensional organoid technology has sprung up and become more and more popular among researchers. Organoids are the miniatures of in vivo tissues and organs, and faithfully re...
-
Article
Open AccessThe role of neoantigen in immune checkpoint blockade therapy
Immune checkpoint inhibitor induces tumor rejection by activated host immune system. The anti-tumor immune response consists of capture, presentation, recognition of neoantigen, as well as subsequent killing o...
-
Article
Develo** TRAIL/TRAIL death receptor-based cancer therapies
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily that can initiate the apoptosis pathway by binding to its associated death receptors DR4 and DR5. The ac...
